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Point-of-care testing (POCT) for glycated haemoglobin (HbA1c) 
enables the clinician to make immediate management decisions 
based on glycaemic control that the patient has achieved over the 
preceding 3 months. These decisions usually entail both lifestyle and 
therapeutic modifications. Pillay et al.[1] have shown that the majority 
of patients with diabetes mellitus (DM) in KwaZulu-Natal Province, 
South Africa (SA), are diagnosed and have their treatment initiated 
at local clinic level. Many of these clinics do not have, or have limited 
access to, HbA1c testing. If testing is available, it often requires a 
formal venous blood sample to be drawn and sent to a laboratory. 
Usually the laboratory is not situated on the clinic premises. Patients 
are then reviewed at a much later date (the delay can range from 
1 week to ≥6  months), and only at that stage are decisions made 
regarding lifestyle and titration of diabetic medications. Suboptimal 
control of DM has been described in both the public and private 
healthcare sectors in SA.[2,3] Poor glycaemic control increases the 
risks of diabetes-related complications.[4] Already poorly controlled 
patients are at further increased risk of developing these complications 
while they wait for HbA1c results.
Tanyanyiwa et al.[5] have previously shown in SA that HbA1c 
results were comparable to standard laboratory testing when using 
the DCA Vantage POCT device.[5] Studies are conflicting with regard 
to whether HbA1c POCT does in fact have a positive impact on 
overall DM control. Al-Ansary et al.[6] in their meta-analysis found 
no significant improvement in HbA1c control using HbA1c POCT, 
although an improvement in patient satisfaction was noted. Other 
similar studies conducted globally indicate definite improvements 
in diabetes control in the groups that received HbA1c POCT.[7-11] 
Laurence et al.[12] found that POCT significantly improved patient 
satisfaction. Limited data on the benefits on diabetes control of 
HbA1c POCT exist in SA. Mash et al.[13] suggested in their report 
on a study conducted in the Western Cape Province that the effects 
of HbA1c POCT should not be evaluated in isolation but rather in 
combination with strategies to improve clinician inertia, coupled with 
stronger primary healthcare.[13] A multifaceted approach to diabetes 
care was introduced at the diabetes clinic at Edendale Hospital 
(EDH), Pietermaritzburg, KwaZulu-Natal, in 2012.[14] Improved 
clinician and nurse education on diabetes, based on the Society for 
Endocrinology, Metabolism and Diabetes of South Africa (SEMDSA) 
guidelines, was integral to this approach.
Objectives
To provide data from SA on the efficacy of using HbA1c POCT 
in a diabetes clinic, and to determine whether there was a positive 
correlation between POCT HbA1c readings and formal laboratory 
HbA1c readings.
Methods
This was a quantitative, interventional quasi-experimental study 
conducted in the diabetes clinic at EDH, a regional-level hospital. 
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Background. Optimal control of diabetes mellitus (DM) remains daunting globally. Point-of-care testing (POCT) for glycated haemoglobin 
(HbA1c) enables the clinician to make immediate management decisions and thereby improve DM control and complications. Better 
control is increasingly being striven for in developing countries where availability of POCT devices is limited.
Methods. Every alternate patient who visited the diabetes clinic at Edendale Hospital, Durban, South Africa, between 1 June 2017 and 
31 August 2017 was invited to participate in the study. These patients made up the POCT group, with the remainder making up the control 
laboratory group. The POCT group had Quo-Test HbA1c POCT done at the clinic visit and their treatment was adjusted based on the 
HbA1c reading, while the control group received standard treatment. The two groups of patients were reviewed at 3 months to identify 
differences in diabetes control between them.
Results. Data from 266 patients were analysed (135 in the POCT group v. 131 in the control group). There was no significant difference 
between the price of the POCT and laboratory HbA1c tests (p=0.823). The POCT and laboratory HbA1c values showed good correlation at 
baseline (r=0.995; p<0.001). The two groups of patients were evenly matched in respect of most demographic and clinical variables. Patients 
in the POCT group showed a significant improvement in mean (standard deviation) glycaemic control between baseline and 3 months (9.61 
(2.46) v. 8.98 (2.15); p<0.043). No improvement was noted in the control group (9.58 (2.49) v. 9.43 (2.15); p=0.823).
Conclusions. The Quo-Test HbA1c POCT had good correlation with standard laboratory methods in respect of both glycaemic control and 
price. Patients who had POCT at baseline showed a significant improvement in glycaemic control at 3 months. HbA1c POCT in the setting 
of a multifaceted approach to diabetes care has been shown to have definite benefits.
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Every alternate patient who presented to the clinic over a 3-month 
period (from 1 June 2017 up to and including 31 August 2017) was 
offered the opportunity to participate in the study. If they accepted 
this invitation, they signed a form giving informed consent to 
participate. If they refused, their diabetes was managed as per the 
normal clinic schedule. Patients who had given informed consent 
(the POCT group) then had their POCT of HbA1c performed as part 
of the normal vital clinical signs. The only difference between the two 
groups was that the POCT group had POCT HbA1c testing done in 
addition to the normal vital clinical signs performed by nursing staff. 
Clinicians working in the diabetes clinic made active management 
decisions in respect of lifestyle modification and intensification of 
pharmacological therapy based on the POCT HbA1c readings. The 
patients who were not recruited into the study (the control group) 
received their routine diabetes management. Both groups of patients 
(control and POCT) had formal venous blood samples drawn. These 
were sent to the National Health Laboratory Service (NHLS), where 
the Bio-Rad D-10 machine (Bio-Rad Laboratories, USA) was used 
to obtain HbA1c values. The machine is National Glycohemoglobin 
Standardisation Program accredited to ensure standardisation of 
HbA1c results.
Both the control and POCT groups of patients were then seen 
after 3 months and the same process was followed. Since September 
2012, all consultations at the EDH diabetes clinic have been done in 
a structured and comprehensive manner using specially designed 
datasheets that are completed for every patient seen at the clinic 
and have been approved for use by the University of KwaZulu-Natal 
Biomedical Research and Ethics Committee (ref. no. 194/95). The 
datasheets are completed in triplicate. One copy of the datasheet is 
given to the patient to take to their local clinic, the second is affixed 
to the patient’s outpatient file, and the third is kept in the clinic. This 
third copy was used as a source document for all the clinical and 
biochemical variables required for completion of this study.
Measurements
POCT was performed using a Quo-Test HbA1c analyser (EKF 
Diagnostics, UK). Reagents were appropriately stored in a refrigerator 
as prescribed by the manufacturer. A finger-prick test is usually 
performed on all patients attending the clinic for random blood 
glucose testing. A second drop of capillary blood from the same 
finger-prick was used for the Quo-Test analyser. HbA1c analysis was 
completed by the machine within 4 minutes. This POCT HbA1c 
reading was entered onto the patient’s datasheet. Both groups of 
patients had all their vital clinical signs performed by the nursing 
staff. These included urine dipstick findings, sitting and standing 
blood pressures (mmHg), resting heart rate (beats per minute), 
height (cm), weight (cm), waist circumference (cm), body mass index 
(BMI, kg/m2) and random glucose measurement (mmol/L) using an 
Accu-Chek glucometer (Roche, Switzerland). Both the POCT and 
control groups of patients had baseline and 3-month venous blood 
samples drawn. These samples were sent to the NHLS for HbA1c 
measurement, a lipogram and renal function tests including the 
glomerular filtration rate.
Data collection and statistical analysis
Continuous variables were documented as mean (standard deviation) 
values. Numbers and percentages were expressed for categorical 
variables. Numerical data were compared using analysis of variance, 
while categorical data relationships were determined using either the 
χ2 or Fisher’s exact tests. A p-value <0.05 was used as indicator of 
significance. Pearson’s correlation was used to measure the strength 
of the linear association between POCT HbA1c and laboratory 
HbA1c testing. Data were analysed using the Statistical Package for 
Social Science (SPSS) version 25 for Windows (SPSS Inc., USA).
Ethical considerations
All patients included in the study signed an informed consent form 
available in both English and isiZulu. All patients were allocated a 
study-specific number to maintain anonymisation of data. The data 
were stored on a password-protected computer.
Ethics approval for this study was obtained from the University of 
KwaZulu-Natal Biomedical Research and Ethics Committee (ref. no. 
BE 491/16).
Results
The POCT and control groups consisted of 135 and 131 patients, 
respectively. Data from a total of 266 patients were analysed for the 
study. There was no significant difference between the cost of the 
Quo-Test HbA1c POCT and the NHLS HbA1c test (ZAR91.20 v. 
ZAR87.78, respectively; p=0.823).
Table 1 provides the demographics and baseline data for both 
groups. Other than for BMI in males, no statistical differences were 
noted between the two groups for the variables listed in Table 1.
Fig. 1 demonstrates that the Quo-Test POCT and laboratory 
HbA1c values showed good correlation at baseline (r=0.995; p<0.001).
Table 2 shows that there was no statistical difference between mean 
HbA1c levels in the POCT group and the laboratory group, both at 
baseline and at the 3-month visit.
Table 3 and Figs 2 and 3 demonstrate that a significant improve-
ment in glycaemic control was noted in the POCT group, while in the 
control group no statistically significant difference could be shown 
between baseline and 3 months.
Discussion
Optimal control of DM remains a problem worldwide. Improved 
diabetes control will ease the burden that the complications of DM 
place on patients and national health budgets. POCT of HbA1c 
has been shown globally to improve overall diabetes control and by 
inference diabetes-related complications.[7-11]
So far, limited studies have been conducted in SA to determine 
whether HbA1c POCT has benefits similar to those documented 
elsewhere. In the report on their study in the Western Cape, Mash 
et al.[13] suggested that POCT for HbA1c showed no benefits in 
improving glycaemic control in public sector primary care practice. 
They further commented that POCT should be re-evaluated in the 
context of an improved multifaceted approach targeting both the 
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Fig. 1. Correlation between POCT and laboratory HbA1c values. (POCT = 
point-of-care testing; HbA1c = glycated haemoglobin).
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clinician and the primary healthcare setting. A multifaceted approach 
of this nature was introduced into the diabetes clinic at EDH in 
2012,[14] to which clinician and nurse re-education on the management 
of DM as prescribed by the local SA guidelines was integral. The EDH 
diabetes clinic therefore provided an excellent setting to investigate 
the effects of HbA1c POCT on diabetes control in the context of 
an already established multifaceted approach. Not surprisingly, we 
demonstrated that patients who received HbA1c POCT testing and 
intensification of therapy (lifestyle and therapeutic) at baseline had 
significant improvements in glycaemic control at 3 months compared 
with the laboratory control group.
Recently, Abbai et al.[15] demonstrated in their study in Durban, 
SA, that there was good correlation between POCT and laboratory 
HbA1c values using the Afinion AS100 point-of-care analyser. 
This study, however, only included patients aged >50 years (mean 
66 years). Tanyanyiwa et al.[5] have previously shown in SA that 
HbA1c results were comparable to standard laboratory testing when 
using the DCA Vantage POCT device.[5] In both these studies, no 
follow-up of patients was performed to assess the effects of POCT 
on diabetes control at a later stage.[5,15] Our study showed good 
correlation between the Quo-Test POCT HbA1c values and NHLS 
laboratory values. Pillay et al.[1] showed that the majority of patients 
with diabetes are diagnosed and have their therapy initiated at 
their local healthcare clinic. HbA1c POCT is often not available 
at resource-limited clinics, so formal venous bloods have to be 
drawn and sent to a laboratory, which may not be situated on the 
premises. The HbA1c results are then only reviewed at the patient’s 
next clinic visit in 1 - 6 months’ time, and only at this visit will 
therapy be modified. Introduction of HbA1c POCT at these clinics 
would provide an excellent avenue to improve overall diabetes 
control and thereby decrease diabetes-related complications. In 
addition to improved diabetes control, availability of point-of-care 
Table 1. Demographics of the patient population
Baseline POCT group Baseline control group p-value
Patients, n 135 131
Male 45 43 0.896
Female 90 88 0.896
Age (years), mean (SD) 53.6 (15.6) 53.7 (16.9) 0.875
Male 48.5 (17.8) 49.5 (18.6) 0.776
Female 56.2 (13.7) 55.7 (15.6) 0.990
Type of DM
Type 1 17 24 0.308
Type 2 116 109 0.308
Duration of DM (years), mean (SD) 9.5 (9.3) 8.8 (7.8) 0.784
Patients with coexisting illnesses, n
Hypertension 90 94 0.691
Chronic kidney disease 21 19 0.864
HIV infection 27 21 0.426
Duration of HIV infection (years), mean (SD) 6.1 (4.6) 7.3 (4.8) 0.394
Patients on antiretrovirals, n 20 19 0.356
Years on ARVs, mean (SD) 4.5 (1.4) 4.6 (1.2) 0.279
Patients with substance use, n
Smoker 8 8 1.000
Consumed alcohol 11 5 0.196
BMI (kg/m2), mean (SD) 32.1 (8.7) 32.1 (7.6) 0.812
Male 26.5 (5.7) 29.5 (7.4) 0.033
Female 35.1 (8.5) 33.5 (7.3) 0.161
Waist circumference (cm), mean (SD) 108.3 (18.3) 109.1 (17.0) 0.638
Male 95.8 (14.6) 101.6 (17.5) 0.088
Female 115.0 (16.5) 112.9 (15.4) 0.413
HbA1c (%), mean (SD) 9.6 (2.4) 9.5 (2.5) 0.819
Blood pressure (mmHg), mean (SD)
Systolic 138.7 (28.1) 146.6 (26.5) 0.014
Diastolic 82.4 (14.0) 85.6 (13.6) 0.104
Total cholesterol (mmol/L), mean (SD) 4.5 (1.4) 4.6 (1.2) 0.279
LDL cholesterol (mmol/L), mean (SD) 2.4 (1.2) 2.5 (1.0) 0.533
Creatinine (mmol/L), mean (SD) 94.5 (48.3) 94.3 (53.0) 0.467
POCT = point-of-care testing; SD = standard deviation; DM = diabetes mellitus; ARVs = antiretrovirals; BMI = body mass index; HbA1c = glycated haemoglobin; LDL = low-density lipoprotein.
Table 2. Mean HbA1c levels in the in POCT and laboratory 
groups
HbA1c (%), mean (SD)
Time POCT group Control group p-value*
Baseline 9.61 (2.46) 9.58 (2.49) 0.793
3 months 8.98 (2.15) 9.43 (2.15) 0.071
HbA1c = glycated haemoglobin; POCT = point-of-care testing; SD = standard deviation.
*Mann-Whitney U-test.
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devices at these clinics would help to improve patient satisfaction 
and compliance.
Study limitations
The follow-up period for this study was only 3 months. It is suggested 
that future prospective studies have a longer follow-up period to 
establish whether improvements as were observed in this study 
persist.
Conclusions
This study showed that POCT of HbA1c with the Quo-Test device 
showed good correlation with laboratory values and that the cost 
was statistically no different to the current NHLS prices. Patients 
who received POCT for HbA1c showed a significant improvement in 
diabetes control after a 3-month period. These findings augur well for 
the roll-out of these devices in local healthcare facilities.
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Table 3. Changes in HbA1c between baseline and 3 months in the POCT and control groups
POCT group
p-value*
Control group
p-value*Baseline 3 months Baseline 3 months
HbA1c (%), mean (SD) 9.61 (2.46) 8.98 (2.15) 0.043 9.58 (2.49) 9.43 (2.15) 0.823
HbA1c = glycated haemoglobin; POCT = point-of-care testing; SD = standard deviation.
*Mann-Whitney U-test.
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Fig. 2. Significant improvement in HbA1c in the POCT group. (POCT = 
point-of-care testing; HbA1c = glycated haemoglobin; SD = standard 
deviation.)
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Fig. 3. No significant difference in HbA1c in the control group. (HbA1c = 
glycated haemoglobin; SD = standard deviation.)
